Please find attached our intimation on captioned subject.
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aarti Pharmalabs reported FY26 standalone revenue of Rs 179,755.17 lakhs, marginally up from Rs 177,135.18 lakhs in FY25. However, profit after tax dropped significantly to Rs 17,620.20 lakhs from Rs 25,734.88 lakhs, representing a 31.5% decline. The company recognized an exceptional item of Rs 279.49 lakhs due to new labour codes impact. Finance costs nearly doubled to Rs 4,690.08 lakhs from Rs 2,563.33 lakhs. The auditors issued an unmodified (clean) opinion, though they included an Emphasis of Matter regarding a foreign exchange derivative contract that was inadvertently excluded from fair value calculations in prior periods, resulting in Q3 FY26 figures being restated with a net impact of Rs 2,224.71 lakhs recognized in FY26. The Board declared a final dividend of Rs 2 per share.
The 31.5% PAT decline despite flat revenue signals margin pressure from higher finance costs and forex losses. The derivative restatement and exceptional items are negatives, though the clean audit opinion provides some comfort. The stock may face pressure given the significant earnings contraction.